Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

Core Viewpoint - Can-Fite BioPharma Ltd. announced positive results from a Phase IIa study of namodenoson for advanced pancreatic ductal adenocarcinoma (PDAC), highlighting its favorable safety profile and potential for further clinical evaluation [1][2][5]. Group 1: Study Results - The Phase IIa study met its primary endpoint of safety, showing that namodenoson was well tolerated in a heavily pretreated patient population with no new safety signals identified [2][3]. - The study enrolled 20 patients with advanced PDAC who had received one or more prior lines of therapy, representing a high-risk population [3]. - Secondary endpoints included overall survival (OS) and progression-free survival (PFS), with ongoing follow-up indicating that one-third of patients were alive at the time of data cut-off [4]. Group 2: Drug Profile and Designation - Namodenoson is a selective A3 adenosine receptor (A3AR) agonist that has shown anti-tumor activity in preclinical models and is also being evaluated for advanced liver cancer [5][6]. - The drug has received Orphan Drug Designation from the U.S. FDA for the treatment of pancreatic cancer, indicating its potential significance in addressing unmet medical needs [6]. Group 3: Company Overview - Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company focused on developing small molecule drugs for cancer and inflammatory diseases, with a pipeline addressing multi-billion dollar markets [7]. - The company’s lead drug candidate, Piclidenoson, has reported topline results in a Phase 3 trial for psoriasis and is advancing in clinical trials for other indications [7].